Caitong International Asset Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Caitong International Asset Management’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$785	Buy	+59	New	+$575	﹤0.01%	1600
2026 Q1	–	Sell	-214	Closed	-$1.6K	–	2732
2025 Q4	$1.6K	Buy	+214	New	+$2.17K	﹤0.01%	1331
2025 Q3	–	Sell	-546	Closed	-$2.03K	–	2134
2025 Q2	$2.03K	Buy	+546	New	+$1.92K	﹤0.01%	1379
2025 Q1	–	Sell	-31	Closed	-$173	–	2279
2024 Q4	$173	Buy	+31	New	+$243	﹤0.01%	1590

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Caitong International Asset Management's FDMT Position: Q2 2026 in Review

Caitong International Asset Management opened a new position in 4D Molecular Therapeutics (FDMT) in Q2 2026: 59 shares worth $785. The stake represents ﹤0.01% of the portfolio and ranks #1600 among its holdings. This is a return to the name: Caitong International Asset Management previously reported a position in FDMT as recently as Q4 2025.

Caitong International Asset Management first reported a position in FDMT in Q4 2024 and has held it in 4 quarters since. The position peaked at $2.03K in Q2 2025. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

Caitong International Asset Management held 59 shares of 4D Molecular Therapeutics worth $785 as of Q2 2026.
4D Molecular Therapeutics was a new Caitong International Asset Management position in Q2 2026.
4D Molecular Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #1600 holding.
Caitong International Asset Management first reported a position in 4D Molecular Therapeutics in Q4 2024 and has held it in 4 quarters since.
Caitong International Asset Management's 4D Molecular Therapeutics position peaked at $2.03K in Q2 2025.
158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.